September 24, 2025 PDF Version ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity
Some days, my body speaks before I’m ready to listen. My balance wobbles, my movements grow sharper, my speech feels slower to form. Living with Huntington’s disease means these aren’t
Earlier today, Skyhawk provided the below update on Part C of their SKY-0515 Phase 1 trial. —-Community Letter—— Dear Skyhawk friends and colleagues, We are delighted to today announce the
1. Morning Grounding Ritual Purpose: Create a calm, intentional start to your day Before my feet touch the floor, I pause. I place my hand over my heart or my
July 25, 2025 NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)– Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for
“You’re such a warrior.” People say it with admiration, as if it’s a badge I should wear proudly. But what if I don’t always want to be a warrior? What
The European Huntington Association, with the support of a grant from the European Union, and in collaboration with the Ligue Huntington Francophone Belge, the Bulgarian Huntington Association and the ACHE
Living with Huntington’s Disease has taught me many things, but one of the most important lessons has been this: presence is a practice. Before my diagnosis, I didn’t give much
May 5, 2025 PDF Version – Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 – – Favorable dose-dependent trends across clinical scales in Stage 2
Every May, communities around the world come together to shine a light on Huntington’s Disease (HD). From families and caregivers to clinicians, researchers, and advocates, we are united by one
September 24, 2025 PDF Version ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity
Some days, my body speaks before I’m ready to listen. My balance wobbles, my movements grow sharper, my speech feels slower to form. Living with Huntington’s disease means these aren’t
Earlier today, Skyhawk provided the below update on Part C of their SKY-0515 Phase 1 trial. —-Community Letter—— Dear Skyhawk friends and colleagues, We are delighted to today announce the
1. Morning Grounding Ritual Purpose: Create a calm, intentional start to your day Before my feet touch the floor, I pause. I place my hand over my heart or my
July 25, 2025 NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)– Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for
“You’re such a warrior.” People say it with admiration, as if it’s a badge I should wear proudly. But what if I don’t always want to be a warrior? What
The European Huntington Association, with the support of a grant from the European Union, and in collaboration with the Ligue Huntington Francophone Belge, the Bulgarian Huntington Association and the ACHE
Living with Huntington’s Disease has taught me many things, but one of the most important lessons has been this: presence is a practice. Before my diagnosis, I didn’t give much
May 5, 2025 PDF Version – Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 – – Favorable dose-dependent trends across clinical scales in Stage 2
Every May, communities around the world come together to shine a light on Huntington’s Disease (HD). From families and caregivers to clinicians, researchers, and advocates, we are united by one
English English 
العربية
Български
简体中文
Čeština
Dansk
Nederlands
Eesti
Suomi
Français
Deutsch
Ελληνικά
Magyar
Bahasa Indonesia
Italiano
日本語
Latviešu valoda
Lietuvių kalba
Polski
Português
Română
Русский
Slovenčina
Slovenščina
Español
Svenska
Türkçe
Українська
